查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1744581

2032 年功效测试市场预测：按产品类型、测试类型、方法、最终用户和地区进行的全球分析

Efficacy Testing Market Forecasts to 2032 - Global Analysis By Product Type (Pharmaceuticals, Cosmetics, Medical Devices and Other Product Types), Test Type, Method, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球功效测试市场预计在 2025 年达到 5.149 亿美元，到 2032 年将达到 9.055 亿美元，预测期内的复合年增长率为 8.4%。

功效测试是对产品性能进行科学评估的过程，以确定其在特定条件下达到预期效果的能力。它涉及透过受控实验来评估产品如何有效地实现其声称的功能，例如控制病虫害或促进农业生长。此类测试对于检验产品声明、确保合规性以及指导使用方法至关重要。功效测试提供了支援产品认证的关键数据，有助于配方改进，并透过已证实的功效建立了使用者信任。

根据美国食品药物管理局（FDA）的数据，2022年至2023年间，因功效或安全性问题而召回的产品数量将增加15％，这促使企业进一步投资于严格的测试通讯协定。

日益严格的监管合规要求

严格的全球监管标准迫使製药和生技公司透过全面的功效测试来检验其产品功效。 FDA 和 EMA 等监管机构在产品核准前越来越重视产品功效。各公司正增加对完善功效测试程序的投资，以降低产品召回和合规性问题的风险。临床试验和非临床试验透明度和课责的提高也强化了这一趋势。因此，功效测试服务正逐渐成为产品开发週期中不可或缺的一部分。

先进测试设备高成本

采用先进的功效测试技术需要大量的资本投入，这限制了中小企业的可近性。影像系统、高通量筛检平台和分子检测等设备高昂的采集费用构成了财务限制。这种成本密集型环境阻碍了市场扩张，尤其是在研发预算有限的新兴经济体。预算限制通常会延迟测试阶段并延长产品开发週期。透过技术创新和租赁模式解决成本障碍，有助于扩大市场渗透。

个人化医疗和生物技术的成长

个人化治疗方法的加速普及需要根据特定患者情况进行精准的疗效测试。各公司正专注于生物标记检验和伴随诊断，以准确评估治疗反应。这种转变为疗效测试提供者提供了实现服务多元化的巨大机会。生物製药领域研发投入的不断增加以及临床试验数量的不断增长进一步加速了这一趋势。客製化化疗效评估正逐渐成为下一代疗法竞争格局中的关键差异化因素。

对传统测试模式的伦理担忧

动物试验和人体功效测试模型通常需要接受伦理审查，这可能会阻碍研究核准。未能解决这些伦理挑战可能会导致法律纠纷，并损害检测实验室的声誉。对符合伦理规范的实践的需求正推动产业向试管内和计算模型发展。此外，全球伦理指南的协调并不一致，这带来了进一步的合规挑战。这项威胁要求创新伦理测试通讯协定，并与相关人员进行透明的沟通。

COVID-19的影响：

此次疫情凸显了功效测试在缩短疫苗和疗法研发週期方面的关键作用。快速检测通讯协定和紧急核准增加了在压缩时限内取得可靠功效数据的需求。这场危机也凸显了远端和自动化测试解决方案对于确保业务永续营运连续性的重要性。从长远来看，新冠疫情已导致功效测试能力的资金筹措和基础设施升级。预计这种转变将在疫情直接影响后维持市场成长。

预计製药业将成为预测期内最大的产业

由于整个药物开发过程都依赖严格的验证方案，预计製药业将在预测期内占据最大的市场占有率。监管部门对疗效的证明要求也进一步促进了该行业的成长。随着针对慢性病和文明病的药物数量不断增加，製药公司正在加大对疗效研究的投资。此外，製药公司与合约研究组织 (CRO) 之间的合作正在简化大规模试验的流程。该行业在确保监管部门核准和市场准入方面发挥战略性作用，从而巩固了主导地位。

预计体外测试部分在预测期内将以最高的复合年增长率成长。

体外检测领域预计将在预测期内实现最高成长，因为它能够提供准确的结果，且无需担心动物试验相关的伦理问题。器官晶片和3D细胞培养技术的创新使体外检测更加可靠且扩充性。个人化医疗的转变将进一步推动对患者特异性体外检测方法的需求。监管部门对替代检测模式的支持也推动了其更广泛的应用。从传统的体内方法向体外平台的转变也推动了该领域的快速扩张。

比最大的地区

由于製药生产和研发活动蓬勃发展，预计亚太地区将在预测期内占据最大的市场占有率。生物技术投资的不断增加以及政府的积极倡议正在培育一个蓬勃发展的测试生态系统。中国、印度和韩国等国家正成为疗效测试服务的主要外包中心。此外，全球製药公司纷纷在亚洲设立研发中心，也进一步巩固了该地区的市场地位。

复合年增长率最高的地区：

预计北美地区在预测期内将呈现最高的复合年增长率，这得益于其先进的医疗基础设施和强有力的法律规范。临床研究和精准医疗计画资金的增加将进一步推动市场扩张。美国和加拿大主要市场参与企业和合约研究组织 (CRO) 的存在增强了该地区的竞争力。此外，对伦理试验模式和数数位化研究平台的日益重视也推动了相关技术的采用。北美快速整合技术进步的能力确保了其作为高成长地区的地位。

免费客製化服务：

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球功效测试市场（依产品类型）

  • 製药
  • 化妆品
  • 医疗设备
  • 其他产品类型

6. 全球功效测试市场（依测试类型）

  • 抗菌和防腐效果测试
    • 快速检测方法
    • 常规测试方法
  • 消毒剂功效测试
    • 表面测试方法
    • 悬浮液测试方法

7. 全球功效测试市场（依方法）

  • 体外测试
  • 体内测试
  • 临床试验
  • 体外研究
  • 其他方法

8. 全球功效测试市场（按最终用户）

  • 医院和临床实验室
  • 受託研究机构（CRO）
  • 农药公司
  • 化妆品製造商
  • 其他最终用户

9. 全球功效测试市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • 3M Group
  • Abbott Analytical
  • Accugen Laboratories, Inc.
  • Almac Group
  • ALS Limited
  • Betco
  • Bioscience Laboratories, Inc.
  • Blutest Laboratories Limited
  • Cantel Medical Corporation
  • SGS SA
  • Steris plc
  • Diversey, Inc.
  • Ecolab Inc.
  • Eurofins Scientific
  • Lucideon
Product Code: SMRC29629

According to Stratistics MRC, the Global Efficacy Testing Market is accounted for $514.9 million in 2025 and is expected to reach $905.5 million by 2032 growing at a CAGR of 8.4% during the forecast period. Efficacy testing is the process of scientifically assessing the performance of a product to determine its ability to achieve intended results under specified conditions. It involves controlled experiments to evaluate how effectively a product performs its claimed function, such as controlling pests, diseases, or enhancing growth in agriculture. This testing is essential for validating product claims, ensuring regulatory compliance, and guiding application practices. Efficacy testing provides critical data that supports product approval, helps refine formulations, and builds user confidence through proven effectiveness.

According to the US Food and Drug Administration (FDA), the number of products recalls due to inefficacy or safety concerns rose by 15% between 2022 and 2023, prompting companies to invest more in rigorous testing protocols.

Market Dynamics:

Driver:

Increasing regulatory compliance requirements

Stringent global regulatory standards are compelling pharmaceutical and biotech companies to validate the effectiveness of their products through comprehensive efficacy testing. Regulatory bodies such as the FDA and EMA have heightened their focus on product efficacy before approval. Companies are increasingly investing in robust efficacy testing procedures to mitigate the risk of product recalls or compliance issues. Enhanced transparency and accountability in clinical and non-clinical trials are reinforcing this trend. Consequently, efficacy testing services are gaining prominence as essential components of product development cycles.

Restraint:

High cost of advanced testing equipment

The adoption of sophisticated efficacy testing technologies entails significant capital investments, limiting their accessibility for small and medium enterprises. High acquisition and maintenance costs associated with equipment such as imaging systems, high-throughput screening platforms, and molecular assays pose financial constraints. This cost-intensive environment can hinder market expansion, particularly in emerging economies with limited R&D budgets. Budget constraints often result in delayed testing phases and extended product timelines. Addressing cost barriers through technological innovation and leasing models could support broader market penetration.

Opportunity:

Growth in personalized medicine and biotechnology sectors

The accelerating adoption of personalized treatment approaches necessitates precise efficacy testing tailored to specific patient profiles. Companies are focusing on biomarker validation and companion diagnostics to evaluate therapeutic responses accurately. This shift is generating substantial opportunities for efficacy testing providers to diversify service offerings. The rising R&D investments in biopharma and increasing clinical trial volumes further amplify this trend. Tailored efficacy evaluations are emerging as a critical differentiator in the competitive landscape of next-gen therapeutics.

Threat:

Ethical concerns over traditional testing models

Efficacy testing models involving animal trials and human subjects often attract ethical scrutiny, potentially hampering study approvals. Failure to address these ethical challenges may lead to legal complications and reputational damage for testing organizations. The demand for ethically sound practices is pushing the industry toward in vitro and computational models. Moreover, global harmonization of ethical guidelines is inconsistent, creating additional compliance challenges. This threat necessitates innovation in ethical testing protocols and transparent communication with stakeholders.

Covid-19 Impact:

The pandemic underscored the critical role of efficacy testing in accelerating vaccine and therapeutic development timelines. Rapid testing protocols and emergency authorizations heightened the demand for reliable efficacy data within compressed timeframes. The crisis also emphasized the importance of remote and automated testing solutions to ensure business continuity. Long-term, COVID-19 has led to increased funding and infrastructure upgrades for efficacy testing capabilities. This shift is expected to sustain market growth beyond the immediate pandemic impact.

The pharmaceuticals segment is expected to be the largest during the forecast period

The pharmaceuticals segment is expected to account for the largest market share during the forecast period, due to its reliance on rigorous validation protocols throughout drug development. Regulatory obligations to demonstrate therapeutic effectiveness further contribute to segmental growth. With an increasing number of drugs targeting chronic and lifestyle diseases, pharmaceutical companies are intensifying investments in efficacy research. Additionally, collaborations between pharma firms and CROs are streamlining large-scale testing initiatives. The segment's strategic role in ensuring regulatory approval and market entry solidifies its leadership position.

The in vitro testing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the In vitro testing segment is predicted to witness the highest growth rate, due to its ability to deliver accurate results without ethical concerns related to animal testing. Innovations in organ-on-chip and 3D cell culture technologies are enhancing in vitro testing reliability and scalability. The shift toward personalized medicine further boosts demand for patient-specific in vitro assays. Regulatory support for alternative testing models is also encouraging broader adoption. The ongoing transition from traditional in vivo approaches to in vitro platforms will continue driving this segment's rapid expansion.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to robust pharmaceutical manufacturing and R&D activities. Growing investments in biotechnology, coupled with favorable government initiatives, are fostering a thriving testing ecosystem. Countries such as China, India, and South Korea are emerging as major outsourcing hubs for efficacy testing services. Additionally, the influx of global pharmaceutical companies establishing R&D centers in Asia further strengthens its market position.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, supported by advanced healthcare infrastructure and strong regulatory oversight. Increasing funding for clinical research and precision medicine programs is further accelerating market expansion. The presence of key market players and CROs in the U.S. and Canada adds to regional competitiveness. Additionally, the growing emphasis on ethical testing models and digitized research platforms is boosting adoption. North America's ability to rapidly integrate technological advancements secures its status as a high-growth region.

Key players in the market

Some of the key players in Efficacy Testing Market include 3M Group, Abbott Analytical, Accugen Laboratories, Inc., Almac Group, ALS Limited, Betco, Bioscience Laboratories, Inc., Blutest Laboratories Limited, Cantel Medical Corporation, SGS SA, Steris plc, Diversey, Inc., Ecolab Inc., Eurofins Scientific, and Lucideon.

Key Developments:

In May 2025, SGS SA introduced an advanced efficacy testing service for antimicrobial coatings, designed for industrial and healthcare applications. The service uses AI-driven analytics to provide rapid and accurate results, ensuring compliance with global regulatory standards.

In April 2025, Eurofins Scientific launched a new high-throughput efficacy testing platform for disinfectants, targeting municipal water treatment facilities. The platform reduces testing time by 30% while maintaining precision for regulatory compliance.

In February 2025, Steris plc introduced a novel efficacy testing protocol for sterilization products, utilizing automated systems to enhance accuracy and speed in validating disinfectant performance for healthcare settings.

Product Types Covered:

  • Pharmaceuticals
  • Cosmetics
  • Medical Devices
  • Other Product Types

Test Types Covered:

  • Antimicrobial/Preservative Efficacy Testing
  • Disinfectant Efficacy Testing

Methods Covered:

  • In Vitro Testing
  • In Vivo Testing
  • Clinical Trials
  • Ex Vivo Testing
  • Other Methods

End Users Covered:

  • Hospitals & Clinical Laboratories
  • Contract Research Organizations (CROs)
  • Agrochemical Companies
  • Cosmetic Manufacturers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Efficacy Testing Market, By Product Type

  • 5.1 Introduction
  • 5.2 Pharmaceuticals
  • 5.3 Cosmetics
  • 5.4 Medical Devices
  • 5.5 Other Product Types

6 Global Efficacy Testing Market, By Test Type

  • 6.1 Introduction
  • 6.2 Antimicrobial/Preservative Efficacy Testing
    • 6.2.1 Rapid Test Method
    • 6.2.2 Traditional Test Method
  • 6.3 Disinfectant Efficacy Testing
    • 6.3.1 Surface Test Method
    • 6.3.2 Suspension Test Method

7 Global Efficacy Testing Market, By Method

  • 7.1 Introduction
  • 7.2 In Vitro Testing
  • 7.3 In Vivo Testing
  • 7.4 Clinical Trials
  • 7.5 Ex Vivo Testing
  • 7.6 Other Methods

8 Global Efficacy Testing Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinical Laboratories
  • 8.3 Contract Research Organizations (CROs)
  • 8.4 Agrochemical Companies
  • 8.5 Cosmetic Manufacturers
  • 8.6 Other End Users

9 Global Efficacy Testing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 3M Group
  • 11.2 Abbott Analytical
  • 11.3 Accugen Laboratories, Inc.
  • 11.4 Almac Group
  • 11.5 ALS Limited
  • 11.6 Betco
  • 11.7 Bioscience Laboratories, Inc.
  • 11.8 Blutest Laboratories Limited
  • 11.9 Cantel Medical Corporation
  • 11.10 SGS SA
  • 11.11 Steris plc
  • 11.12 Diversey, Inc.
  • 11.13 Ecolab Inc.
  • 11.14 Eurofins Scientific
  • 11.15 Lucideon

List of Tables

  • Table 1 Global Efficacy Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Efficacy Testing Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Efficacy Testing Market Outlook, By Pharmaceuticals (2024-2032) ($MN)
  • Table 4 Global Efficacy Testing Market Outlook, By Cosmetics (2024-2032) ($MN)
  • Table 5 Global Efficacy Testing Market Outlook, By Medical Devices (2024-2032) ($MN)
  • Table 6 Global Efficacy Testing Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 7 Global Efficacy Testing Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 8 Global Efficacy Testing Market Outlook, By Antimicrobial/Preservative Efficacy Testing (2024-2032) ($MN)
  • Table 9 Global Efficacy Testing Market Outlook, By Rapid Test Method (2024-2032) ($MN)
  • Table 10 Global Efficacy Testing Market Outlook, By Traditional Test Method (2024-2032) ($MN)
  • Table 11 Global Efficacy Testing Market Outlook, By Disinfectant Efficacy Testing (2024-2032) ($MN)
  • Table 12 Global Efficacy Testing Market Outlook, By Surface Test Method (2024-2032) ($MN)
  • Table 13 Global Efficacy Testing Market Outlook, By Suspension Test Method (2024-2032) ($MN)
  • Table 14 Global Efficacy Testing Market Outlook, By Method (2024-2032) ($MN)
  • Table 15 Global Efficacy Testing Market Outlook, By In Vitro Testing (2024-2032) ($MN)
  • Table 16 Global Efficacy Testing Market Outlook, By In Vivo Testing (2024-2032) ($MN)
  • Table 17 Global Efficacy Testing Market Outlook, By Clinical Trials (2024-2032) ($MN)
  • Table 18 Global Efficacy Testing Market Outlook, By Ex Vivo Testing (2024-2032) ($MN)
  • Table 19 Global Efficacy Testing Market Outlook, By Other Methods (2024-2032) ($MN)
  • Table 20 Global Efficacy Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 21 Global Efficacy Testing Market Outlook, By Hospitals & Clinical Laboratories (2024-2032) ($MN)
  • Table 22 Global Efficacy Testing Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 23 Global Efficacy Testing Market Outlook, By Agrochemical Companies (2024-2032) ($MN)
  • Table 24 Global Efficacy Testing Market Outlook, By Cosmetic Manufacturers (2024-2032) ($MN)
  • Table 25 Global Efficacy Testing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.